Business
RedChip to Host Exclusive Investor Webinar Featuring Lantern Pharma on August 26
ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive live investor webinar with Lantern Pharma Inc. ...
About this update from Lantern Pharma Inc.
[{"type":"text","content":"ORLANDO, FLORIDA / ACCESS Newswire / August 19, 2025 / RedChip Companies, an international investor relations, media, and research firm focused on microcap and small-cap companies, will host an exclusive live investor webinar with Lantern Pharma Inc. (NASDAQ:LTRN) on August 26, 2025, at 4:15 p.m. ET.","length":301,"tagName":"p"},{"type":"text","content":"The webinar will showcase how Lantern is redefining the future of cancer drug discovery and development through its proprietary AI and machine learning platform, RADR®, which analyzes more than 200 billion oncology data points and leverages 200+ advanced ML algorithms to compress early drug development timelines by up to 70% and reduce costs by 80%.","length":351,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/LTRN/84339180112","length":96,"tagName":"p"},{"type":"text","content":"During the webinar, Panna Sharma, CEO of Lantern Pharma, will spotlight the company's advancing clinical pipeline, including:","length":129,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"LP-300: Phase 2 Harmonic™ trial in never-smokers with NSCLC, a $4B+ global market with urgent unmet need.","length":105,"tagName":"p"}]},{"val":[{"type":"text","content":"LP-184: A Phase 1 "blockbuster potential" therapy for DDR-deficient solid tumors, addressing a $10B+ market.","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"LP-284: A first-in-class drug candidate for aggressive lymphomas, including mantle cell lymphoma and high-grade B-cell lymphoma, with $3.75-4B market potential.","length":160,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":383,"olType":false},{"type":"text","content":"With 11 FDA designations, an expanding ADC program, collaborations with world-class cancer centers (including Johns Hopkins and MD Anderson), and a growing patent estate of 100+ issued and pending patents, Lantern is emerging as a leading global AI drug discovery company.","length":272,"tagName":"p"},{"type":"text","content":"A live Q&A session with management will follow the presentation.","length":68,"tagName":"p"},{"type":"text","content":"To register for the free webinar, please visit: https://www.redchip.com/webinar/LTRN/84339180112","length":96,"tagName":"p"},{"type":"text","content"...